

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1-97. (Canceled)
98. (Previously Presented) A monoclonal antibody designated PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) or a fragment of antibody PA14 which binds to an epitope of chemokine receptor 5 (CCR5) present on the surface of a cell expressing CCR5, which epitope comprises a combination of amino acid residues in (a) the N-terminus of CCR5, and (b) the second extracellular loop of CCR5.
99. (Previously Presented) A hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) which produces a monoclonal antibody designated PA14.
100. (Previously Presented) A monoclonal antibody or a fragment of such antibody, wherein the antibody or the fragment of such antibody binds to the same epitope as monoclonal antibody PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB12610).
101. (Currently Amended) A monoclonal antibody or a fragment of such antibody ~~consisting of~~ comprising complementarity determining regions (CDRs) wherein said CDRs are derived from the hybridoma cell line designated PA14 (ATCC Accession No. HB12610).
102. (Previously Presented) The monoclonal antibody according to

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 3

claim 100, wherein the antibody is a humanized antibody.

103. (Currently Amended) The monoclonal antibody according to claim 102, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule.

104. (Currently Amended) The monoclonal antibody according to claim 103, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule ~~is~~ selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

105-117. (Canceled)

118. (Previously Presented) The monoclonal antibody according to claim 101, wherein the antibody is a humanized antibody.

119. (Currently Amended) The monoclonal antibody according to claim 135 ~~118~~, wherein the humanized antibody comprises a framework from a human IgG2 immunoglobulin molecule.

120. (Currently Amended) The monoclonal antibody according to claim 135 ~~118~~, wherein the humanized antibody comprises a framework from a human IgG4 immunoglobulin molecule.

121. (Currently Amended) The monoclonal antibody according to claim 104, wherein the humanized antibody comprises a framework from a human IgG2 immunoglobulin molecule.

122. (Currently Amended) The monoclonal antibody according to claim 104, wherein the humanized antibody comprises a framework from a human IgG4 immunoglobulin molecule.

123. (Previously Presented) The monoclonal antibody according to claim 100, wherein the antibody is a chimeric antibody.

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 4

124. (Previously Presented) The monoclonal antibody according to claim 101, wherein the antibody is a chimeric antibody.
125. (Currently Amended) The monoclonal antibody according to claim 136 ~~123~~, wherein the chimeric antibody comprises a framework from a human IgG2 immunoglobulin molecule.
126. (Currently Amended) The monoclonal antibody according to claim 136 ~~123~~, wherein the chimeric antibody comprises a framework from a human IgG4 immunoglobulin molecule.
127. (Currently Amended) The monoclonal antibody according to claim 137 ~~124~~, wherein the chimeric antibody comprises a framework from a human IgG2 immunoglobulin molecule.
128. (Currently Amended) The monoclonal antibody according to claim 137 ~~124~~, wherein the chimeric antibody comprises a framework from a human IgG4 immunoglobulin molecule.
129. (Previously Presented) The monoclonal antibody fragment according to claim 100, wherein the antibody fragment is a fragment of a humanized antibody.
130. (Previously Presented) The monoclonal antibody fragment according to claim 101, wherein the antibody fragment is a fragment of a humanized antibody.
131. (Currently Amended) The monoclonal antibody fragment according to claim 138 ~~129~~, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.
132. (Currently Amended) The monoclonal antibody fragment according to claim 138 ~~129~~, wherein the humanized antibody fragment

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 5

comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.

133. (Currently Amended) The monoclonal antibody fragment according to claim 139 ~~130~~, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.

134. (Currently Amended) The monoclonal antibody fragment according to claim 139 ~~130~~, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.

135. (New) The monoclonal antibody according to claim 118, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

136. (New) The monoclonal antibody according to claim 123, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

137. (New) The monoclonal antibody according to claim 124, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

138. (New) The monoclonal antibody according to claim 129, wherein the humanized antibody comprises a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.

139. (New) The monoclonal antibody according to claim 130, wherein

Applicants: William C. Olson and Paul J. Maddon
Serial No.: 09/594,983
Filed June 15, 2000
Page 6

the humanized antibody comprises a framework from a human immunoglobulin molecule selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.